Michael Brown, MD
Radiation Oncology · Lewiston, MENPI 1235101825
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $741, more than ten times the $34 reported in 2021.
Across 73 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$351
- Johnson & Johnson$146
- Astellas Pharma US Inc$122
- Novocure Inc.$122
- Lilly USA, LLC$103
- AbbVie$70
- plus $751 from 21 others
What the payments were for
- Food & beverage$1,665100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $351 |
| Johnson & Johnson | 7 | $146 |
| Astellas Pharma US Inc | 6 | $122 |
| Novocure Inc. | 5 | $122 |
| Lilly USA, LLC | 4 | $103 |
| AbbVie | 3 | $70 |
| Amgen | 3 | $65 |
| Genentech USA, Inc. | 2 | $53 |
| Karyopharm Therapeutics Inc. | 2 | $45 |
| Pfizer | 2 | $44 |
| Syndax Pharmaceuticals, Inc. | 2 | $44 |
| Progenics Pharmaceuticals, Inc. | 2 | $43 |
| Merck | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Pharmacosmos Therapeutics Inc. | 1 | $37 |
| Novartis | 2 | $36 |
| GSK | 2 | $35 |
| EMD Serono, Inc. | 2 | $33 |
| Stemline Therapeutics Inc. | 2 | $33 |
| Coherus Oncology, Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Taiho Oncology, Inc. | 1 | $26 |
| Gilead | 1 | $23 |
| Myriad Genetic Laboratories, Inc. | 1 | $22 |
| Exelixis Inc. | 1 | $22 |
| Bayer | 1 | $21 |
How this compares
Too few radiation oncology providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cevimeline Hcl | 19 | $2,430 |
| Tamsulosin Hcl | 119 | $1,498 |
| Oxybutynin Chloride ErOxybutynin Chloride | 63 | $1,498 |
| Oxycodone Hcl | 49 | $564 |
| Bicalutamide | 24 | $513 |
| Sucralfate | 30 | $499 |
| Lidocaine Hcl ViscousLidocaine Hcl | 26 | $408 |
| SsdSilver Sulfadiazine | 11 | $379 |
| Dexamethasone | 11 | $258 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $246 |
| Pantoprazole Sodium | 11 | $188 |
| Betamethasone Valerate | 15 | $145 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Lewiston
- Courtney JensenLewiston$601
- John DrogosAugusta$540
- Kurt SnyderBrewer$485
- Janeen DanielsBrewer$399
- Whitney BeelerPortland$341
- Michael MilliganPortland$295
- Sujana GottumukkalaPortland$284
- Julia ManzerovaBrewer$239
- Ian BristolPortland$114
- Naghmeh IsfahanianPresque Isle$93
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.